CHRONIC
PANCREATITIS –
- is a self perpetuaring disease characterised by
pain and ultimately by pancreatic exocrine or endocrine insufficiency.
Chronic
inflammatory disease of the pancreas may present as episodes of acute
inflammation in a previously injured pancreas or as chronic damage with persistent pain or malabsorption.
The causes of
relapsing chronic pancreatitis are similar to those of acute pancreatitis (Table 294-1), except
that there is an appreciable incidence of cases of undetermined origin. In
addition, the pancreatitis associated with gallstones is predominantly acute or
relapsing-acute in nature. A cholecystectomy is almost always performed in patients
after the first or second attack of gallstone-associated pancreatitis.
Patients with
chronic pancreatitis may present with persistent abdominal pain, with or
without steatorrhea; some (~15%) present with steatorrhea and no pain.
Patients with
chronic pancreatitis in whom there is extensive destruction of the pancreas
(<10% of exocrine function remaining) have steatorrhea and azotorrhea.
Among
American adults, alcoholism is the most common cause of clinically
apparent pancreatic exocrine insufficiency, while cystic fibrosis is the most
frequent cause in children. In up to 25% of American adults with chronic
pancreatitis, the cause is not known; that is, they have idiopathic chronic
pancreatitis. Indeed, idiopathic chronic pancreatitis is the leading cause
of nonalcoholic chronic pancreatitis in adults in the United States .
In a recent series, genetic testing was done on 39 patients with idiopathic
chronic pancreatitis. Seventeen patients had CFTR mutations and 9 had mutations
in a trypsin inhibitor gene (PSTI). Pancreatitis risk
was increased 14-fold by having the PSTI mutation, 40-fold by having two
abnormal copies of CFTR, and 600-fold by having both. Thus, the risk of
pancreatitis showed complex inheritance and was highest in individuals who had
abnormalities in both the pancreatic ducts (CFTR) and acini (PSTI). These
findings suggest that PSTI is a modifier gene for CFTR-related idiopathic
chronic pancreatitis. Current knowledge indicates that about 15% of patients
with idiopathic chronic pancreatitis have a genetic basis for this disorder.
The
therapeutic and prognostic implication of these findings remain to be
determined.
In other
parts of the world, severe protein-calorie malnutrition is a common
cause.
In certain
countries, particularly Japan
and Italy ,
there has been an increased interest in autoimmune chronic pancreatitis.
The Japanese describe a distinct entity that is associated with the presence of
autoantibodies in the blood, elevated levels of serum IgG, association with
other autoimmune disorders such as primary biliary cirrhosis and inflammatory
bowel disease, diffuse enlargement of the pancreas, and irregular narrowing of
the main pancreatic duct. Symptoms are usually mild without acute relapsing
attacks of pancreatitis, and patients usually experience a good therapeutic
response to glucocorticoids. It is noteworthy that pancreatic pseudocysts
and calcification within the pancreas are unusual. Although this kind of
pancreatitis is not very common in the United States , all major medical centers
are seeing examples of autoimmune chronic pancreatitis.
Table lists other causes of pancreatic exocrine
insufficiency, but they are relatively uncommon.
TABLE 294-5 Causes of Pancreatic Exocrine Insufficiency
|
|||
|
PATHOPHYSIOLOGY
The events
that initiate an inflammatory process in the pancreas are still not well
understood, and the many hypotheses will not be reviewed here. In the case of
alcohol-induced pancreatitis, it has been suggested that the primary defect may
be the precipitation of protein (inspissated enzymes) in the ducts. The
resulting ductal obstruction could lead to duct dilation, diffuse atrophy of
the acinar cells, fibrosis, and eventual calcification of some of the protein
plugs. However, the fact that some alcoholic patients with recurrent acute
pancreatitis show no evidence of chronic pancreatitis does not support this
hypothesis. In fact, experimental and clinical observations have shown that
alcohol has direct toxic effects on the pancreas. While patients with
alcohol-induced pancreatitis generally consume large amounts of alcohol, some
consume very little (≤50 g/d). Thus prolonged consumption of “socially
acceptable” amounts of alcohol is compatible with the
development of pancreatitis. In addition, the finding of extensive pancreatic
fibrosis in patients who died during their first attack of clinical acute
alcohol-induced pancreatitis supports the concept that such patients already
have chronic pancreatitis.
CLINICAL FEATURES
Patients with
relapsing chronic pancreatitis may present with symptoms identical to those of
acute pancreatitis, but pain may be continuous, intermittent, or absent.
The pathogenesis of this pain is poorly understood.
Although the
classic description is of
-
epigastric pain radiating through the back,
-
the pain pattern is often atypical; the pain
may be worst in the right or left upper quadrant of the back or may be diffuse
throughout the upper abdomen;
-
it may even be referred to the anterior chest or
flank.
Characteristically it is
persistent, deep-seated, and unresponsive to antacids. It often is worsened
by ingestion of alcohol or a heavy meal (especially one rich in fat). Often the
pain is severe enough to necessitate the frequent use of narcotics.
Weight loss,
abnormal stools, and other signs or symptoms suggestive of malabsorption are
common in chronic pancreatitis.
However,
clinically apparent deficiencies of fat-soluble vitamins are surprisingly rare.
The physical findings in these
patients are usually not impressive, so that there is a disparity between the
severity of the abdominal pain and the physical signs (other than some
abdominal tenderness and mild temperature elevation).
DIAGNOSTIC EVALUATION
In contrast
to relapsing acute pancreatitis, the serum amylase and lipase levels are
usually not elevated in chronic pancreatitis. Elevations of serum bilirubin
and alkaline phosphatase levels may indicate cholestasis secondary to chronic
inflammation around the common bile duct (Fig. 294-3).
Many patients
demonstrate impaired glucose tolerance, and some have an elevated
fasting blood glucose level.
|
FIGURE
294-3 Radiologic abnormalities in chronic pancreatitis. A.
Pancreatic calcification (arrows) and stenosis
(tapering) of the intrahepatic portion of the common bile duct demonstrated
by percutaneous transhepatic cholangiography. B.
Pancreatic calcification (large white arrow)
demonstrated by sonography. Note dilated pancreatic duct (thin
white arrow) and splenic vein (open arrow). C. Pancreatic calcification (vertical
arrows) and dilated pancreatic duct (horizontal
arrow) demonstrated by CT scan. D. Endoscopic
retrograde cholangiogram shows grossly dilated pancreatic ducts (arrows) in a patient with long-standing pancreatitis.
|
The classic triad of pancreatic
calcification, steatorrhea, and diabetes mellitus usually establishes the
diagnosis of chronic pancreatitis and exocrine pancreatic insufficiency but is
found in fewer than one-third of chronic pancreatitis patients. Accordingly, it
is often necessary to perform an intubation test such as the secretin
stimulation test, which usually gives abnormal results when 60% or more
of pancreatic exocrine function has been lost. Approximately 40% of patients
with chronic pancreatitis have cobalamin (vitamin B12) malabsorption, which can be corrected
by the administration of oral pancreatic enzymes. There is usually a marked
excretion of fecal fat (Chap. 275), which can
be reduced by the administration of oral pancreatic enzymes. The serum
trypsinogen (Chap. 293) and the
D-xylose urinary excretion test are useful in patients with “pancreatic
steatorrhea,” since the trypsinogen level will be abnormal, and D-xylose
excretion is usually normal. A decreased serum trypsinogen (<20 ng/mL) or a
fecal elastase level of <100 µg/mg of stool strongly suggests severe
pancreatic exocrine insufficiency.
The
radiographic hallmark of chronic pancreatitis is the presence of scattered
calcification throughout the pancreas (Fig. 294-3). Diffuse
pancreatic calcification indicates that significant damage has occurred and
obviates the need for a secretin test. While alcohol is by far the most common
cause, pancreatic calcification may also be seen in cases of severe
protein-calorie malnutrition, hereditary pancreatitis, posttraumatic
pancreatitis, hyperparathyroidism, islet cell tumors, and idiopathic chronic
pancreatitis. A large prospective study has shown convincingly that pancreatic
calcification decreases or even disappears spontaneously in one-third of
patients with severe chronic pancreatitis; this outcome may also follow ductal
decompression. Pancreatic calcification is a dynamic process that is
incompletely understood.
Sonography, CT, and ERCP greatly aid
the diagnosis of pancreatic disease. In addition to excluding pseudocysts and
pancreatic cancer, sonography and CT may show calcification or dilated ducts
associated with chronic pancreatitis (Fig. 294-4). ERCP and
endoscopic ultrasound (EUS) are procedures that provide information about the
main pancreatic duct and the smaller ducts. EUS is also useful in evaluating
the pancreatic parenchyma. In patients with alcohol-induced pancreatitis, ERCP may
reveal a pseudocyst missed by sonography or CT.
|
FIGURE
294-4 Chronic pancreatitis and pancreatic calculi: CT scan and ERCP
appearance. A. In this contrast-enhanced CT scan of
the abdomen, there is evidence of an atrophic pancreas with multiple
calcifications (arrows). Note the markedly dilated
pancreatic duct seen in this section through the body and tail (open arrows). B. ERCP in the same
patient demonstrates the dilated pancreatic duct as well as an
intrapancreatic duct calculus (arrows). These findings correlate
nicely with the CT scan appearance.
|
COMPLICATIONS OF CHRONIC PANCREATITIS
The complications of chronic
pancreatitis are protean.
- Cobalamin
(vitamin B12) malabsorption occurs in 40% of patients with
alcohol-induced chronic pancreatitis and in virtually all with cystic fibrosis.
It is consistently corrected by the administration of pancreatic enzymes
(containing proteases). It may be due to excessive binding of cobalamin by
cobalamin-binding proteins other than intrinsic factor, which ordinarily are
destroyed by pancreatic proteases and therefore do not compete with intrinsic
factor for cobalamin binding.
- Although
most patients show impaired glucose tolerance, diabetic ketoacidosis and
coma are uncommon.
- Similarly,
end-organ damage (retinopathy, neuropathy, nephropathy) is also uncommon, and
the appearance of these complications should raise the question of concomitant
genetic diabetes mellitus. A nondiabetic retinopathy, peripheral in location
and secondary to vitamin A and/or zinc deficiency, is common in these patients.
Effusions containing high concentrations of amylase may occur into the pleural,
pericardial, or peritoneal space.
- Gastrointestinal
bleeding may occur from peptic ulceration, gastritis, a pseudocyst eroding into
the duodenum, or ruptured varices secondary to splenic vein thrombosis due to
inflammation of the tail of the pancreas.
- Icterus may
occur, caused either by edema of the head of the pancreas, which compresses the
common bile duct, or by chronic cholestasis secondary to a chronic inflammatory
reaction around the intrapancreatic portion of the common bile duct (Fig. 294-3). The
chronic obstruction may lead to cholangitis and ultimately to biliary
cirrhosis. Subcutaneous fat necrosis may appear as tender red nodules on the
lower extremities. Bone pain may be secondary to intramedullary fat necrosis.
Inflammation of the large and small joints of the upper and lower extremities
may occur. The incidence of pancreatic carcinoma is increased in patients with chronic
pancreatitis who have been followed for 2 or more years. Twenty years after the
diagnosis of chronic pancreatitis, the cumulative risk of pancreatic carcinoma
is 4%. Perhaps the most common and troublesome complication is addiction to
narcotics.
Supportive
measures include diet restriction and pain medications. The diet should be
moderate in fat (30%), high in protein (24%), and low in carbohydrate (40%).
Restriction of long-chain triglyceride intake can help patients who do not
respond satisfactorily to pancreatic enzyme therapy. Use of foods containing
mainly medium-chain fatty acids, which do not require lipase for digestion, may
be beneficial.
Therapy for
patients with chronic pancreatitis is directed toward two major problems—pain and maldigestion.
Patients with
intermittent attacks of pain are treated essentially like those with acute
pancreatitis (see above). Patients with severe and persistent pain should avoid
alcohol completely and avoid large meals rich in fat. Since the pain is often
severe enough to require frequent use of narcotics (and hence addiction), a
number of surgical procedures have been developed for pain relief. ERCP allows
the surgeon to plan the operative approach. If there is a stricture of the
pancreatic duct, a local resection may ameliorate the pain. Unfortunately,
isolated localized strictures are not common. In most patients with
alcohol-induced disease, the pancreas is diffusely involved, and surgically
correctible localized ductal disease is rare. When there is primary ductal
obstruction and dilation, ductal decompression may provide effective pain
palliation. Short-term pain relief may be achieved in up to 80% of patients,
while long-term pain relief occurs in approximately 50%. In some of these
patients, however, pain relief can be achieved only by resecting 50 to 95% of
the gland. Although pain relief is achieved in three-quarters of these
patients, they tend to develop pancreatic endocrine and exocrine insufficiency
and must be treated with pancreatic enzyme replacement therapy. It is important
to screen patients carefully, for such radical surgery is contraindicated in
those who are severely depressed or suicidal or who continue to drink.
Procedures such as splanchnicectomy, celiac ganglionectomy, and nerve blocks
usually bring only temporary relief and are not recommended. Endoscopic
treatment of chronic pancreatitis may involve sphincterotomy of the minor or
major pancreatic sphincter, dilatation of strictures, removal of calculi, or
stenting of the ventral or dorsal pancreatic duct. Although many of these
techniques are technically impressive, none has been subjected to a randomized
trial in patients with chronic pancreatitis. In addition, significant
complications—acute pancreatitis, pancreatic abscess, damage to the pancreatic
duct, and death—have occurred in up to 36% of patients after stent placement.
Three
double-blind trials have demonstrated that administration of pancreatic enzymes
decreases abdominal pain in selected patients with chronic pancreatitis. In
these trials, approximately 75% of the patients evaluated experienced pain
relief. The patients most likely to respond are those with mild to moderate
exocrine pancreatic dysfunction, as evidenced by an abnormal secretin test,
normal fat absorption, and minimal abnormalities on ERCP examination. These
clinical observations seem to fit with data from humans and experimental
animals demonstrating a negative feedback regulation for pancreatic exocrine
secretion controlled by the amount of proteases within the lumen of the
proximal small intestine. It seems reasonable to use the following approach for
patients with severe, persistent, or continuous abdominal pain thought to be
caused by chronic pancreatitis. After other causes of abdominal pain (peptic ulcer,
gallstones, etc.) have been excluded, a pancreatic sonogram should be done. If
no mass is found, a secretin test may be performed, because its results are
usually abnormal in cases of chronic pancreatitis with pain. If the results are
abnormal (i.e., decreased bicarbonate concentration or volume output), a 3- to
4-week trial of pancreatic enzyme administration is appropriate. Four to eight
conventional tablets or capsules are taken at meals and at bedtime. There are a
number of studies suggesting that patients may have small-duct chronic
pancreatitis and chronic abdominal pain with a normal appearance on
radiographic evaluations (ultrasound, CT, ERCP) but abnormal results on hormone
stimulation tests (secretin test) and/or abnormal pancreatic histology. Such
minimal-change chronic pancreatitis may respond well to pancreatic enzyme
therapy (non-enteric-coated) for relief of abdominal pain. If no relief is
obtained, and especially if the volume secreted during the secretin test is
very low, ERCP or EUS should be performed. If a pseudocyst or a localized
ductal obstruction is found, surgery should be considered. A patient who has
dilated ducts may be a candidate for a surgical ductal decompression procedure.
This procedure provides short-term relief in up to 80% of patients, although
long-term results are closer to 50%. Some studies have shown octreotide to be
effective in decreasing abdominal pain in patients with severe large-duct
disease. If no surgically remediable lesion is found and severe pain continues
despite abstinence from alcohol, subtotal pancreatic resection may be
necessary.
The treatment
of maldigestion rests on the use
of pancreatic enzyme replacement therapy. Diarrhea and steatorrhea are
usually improved by this treatment, although the steatorrhea may not be
completely corrected. The major problem is delivering enough active enzyme into
the duodenum. Steatorrhea could be abolished if 10% of the normal amount of
lipase could be delivered to the duodenum at the proper time. This
concentration of lipase cannot be achieved with the current preparations of
pancreatic enzymes, even if the latter are given in large doses. The reason for
these poor results may be that lipase is inactivated by gastric acid, that food
empties from the stomach faster than do the pancreatic enzymes, and that
batches of commercially available pancreatic extracts vary in enzyme activity.
For the usual
patient, two or three enteric-coated capsules or eight conventional
(non-enteric-coated) tablets of a potent enzyme preparation should be
administered with meals. The usual dose is 30000units of lipase in capsules
(Kreon, mesim-forte).
Some patients
using conventional tablets require adjuvant therapy to improve enzyme
replacement treatment. H2 receptor antagonists (ranitidine, 150 mg
twice daiky), sodium bicarbonate (650 mg before and after meals), and proton
pump inhibitors (e.g, omeprazole, 20-60 mg daily) are effective adjuvants.
Antacids containing calcium carbonate or
magnesium hydroxide are not effective and may actually result in increased
steatorrhea. Several publications have reported colonic strictures
in patients with cystic fibrosis receiving extraordinarily high doses of
high-potency pancreatic enzyme preparations. Such lesions have not been
reported in adults with chronic pancreatitis.
Nonnarcotic analgesics should be
emphasized (Baralgin 5,0 I|v or i|m, Spasmolgon 5,0 I|v or i|m). Patients
taking narcotic drugs for pain relief often become addicted and continue to
have pain.
Prognosis
Patients with
severe exocrine pancreatic insufficiency secondary to alcohol who continue to
drink have a high mortality rate (in one series, 50% of patients who were
followed for 5 to 12 years died during this period) and significant morbidity
(weight loss, lassitude, vitamin deficiency, and narcotic addiction).
Chronic
pancreatitis carries significant medical and social costs. A recent study found
that pancreatitis led to retirement in 11% of patients with the disease,
accounting for 45% of all retirements. In 87% of patients with chronic
pancreatitis unable to maintain gainful employment, alcoholism was a
contributing factor. Patients with chronic pancreatitis also use substantial
medical resources. In 1987 in the United States , this diagnosis
accounted for 122,000 recorded outpatient visits and 56,000 hospital
admissions. Pain may abate if progressive severe exocrine insufficiency
continues. Patients who abstain from alcohol and use vigorous replacement
therapy for maldigestion do reasonably well.
Medical
management of the hyperlipidemias frequently associated with the condition may
also prevent recurrent attacks of pancreatitis.